CRITICAL REVIEW IN PHARMACEUTICAL SCIENCES A Review on Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus (original) (raw)
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
Cody VanNorman
Drug Design Development and Therapy, 2014
View PDFchevron_right
Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
Marissa Salvo
Patient Preference and Adherence, 2014
View PDFchevron_right
Dapagliflozin: A Novel Therapeutic Approach to Treat Diabetes
Aditya Rattan
JMS SKIMS, 2011
View PDFchevron_right
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial
Vincent Woo
Diabetic Medicine, 2014
View PDFchevron_right
Dapagliflozin for the Treatment of Type 2 Diabetes
Arinze Okere
Annals of Pharmacotherapy, 2012
View PDFchevron_right
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
Marc Pfister
2009
View PDFchevron_right
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Arnaud Bastien
The Lancet, 2010
View PDFchevron_right
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Jose Nicolau
New England Journal of Medicine, 2018
View PDFchevron_right
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
JoAnne Saye
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2012
View PDFchevron_right
Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels
jafer palaki
Frontiers in Clinical Diabetes and Healthcare, 2021
View PDFchevron_right
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
eva vivian
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016
View PDFchevron_right
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
Marc Pfister
Diabetes, Obesity and Metabolism, 2010
View PDFchevron_right
Literature review efektivitas dan keamanan dapagliflozin pada pasien diabetes melitus komplikasi
intan permatasari
2020
View PDFchevron_right
Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
Chin-hsiao Tseng
PeerJ, 2020
View PDFchevron_right
Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
Gabriela Cortes
Cardiovascular Endocrinology & Metabolism, 2021
View PDFchevron_right
Dapagliflozin: Clinical practice compared with pre-registration trial data
Neil Munro
British Journal of Diabetes & Vascular Disease, 2014
View PDFchevron_right
Medications for Hyperglycemia in Type 2 Diabetes and Review of Insulin Degludec and Dapagliflozin
Sheikh Salahuddin Ahmed
View PDFchevron_right
Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience
vincenzo provenzano, Gabriella Saura, Alessandro Scorsone
2018
View PDFchevron_right
Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
Nobuya Hayashi
Diabetes Therapy, 2013
View PDFchevron_right
Dapagliflozin: Glucuretic action and beyond
Sundram Karupiah
Pharmacological Research, 2014
View PDFchevron_right
Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study
Cristobal Morales
Drugs in Context, 2022
View PDFchevron_right
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
Arnaud Bastien
Diabetes Care, 2009
View PDFchevron_right
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
Ileana Baldi
Diabetes, obesity & metabolism, 2018
View PDFchevron_right
The Emerging Role of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes. Focus on Dapagliflozin
Cristian Serafinceanu
Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2016
View PDFchevron_right
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects
Marc Pfister
2009
View PDFchevron_right
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
Vincent Woo
Diabetes Care, 2009
View PDFchevron_right
Efficacy and Side Effect Profile of Empagliflozin and Dapagliflozin in Combination Therapy: A Real-World Experience
Mustafa Koçak
The Turkish Journal of Endocrinology and Metabolism, 2021
View PDFchevron_right
Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy
Juan Albisu
2020
View PDFchevron_right